NCT03058289 - A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

February 22, 2023

Study Completion Date

February 22, 2023

Conditions

Breast CancerHead and Neck CancerSquamous Cell CarcinomaLymphomaPancreatic CancerLiver CancerColon CancerLung CancerBile Duct CancerChordoma of SacrumSarcoma

Interventions

DRUG

INT230-6

"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations."

BIOLOGICAL

anti-PD-1 antibody

The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2

BIOLOGICAL

anti-CTLA-4 antibody

The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC

Trial Locations (8)

10032

Columbia University Medical Center, New York

21205

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

77030

Center for Oncology and Blood Disorders, Houston

90033

USC Norris, Los Angeles

92663

USC HOAG, Newport Beach

01655

UMASS Memorial Medical Center, Worcester

19111-2497

Fox Chase Cancer Center, Philadelphia

M5G 1Z5

Princess Margaret Cancer Center - University Health Network, Toronto